Connect with us

Technology

Marengo Secures ESMO 2026 Oral Presentation for Key Phase 2 Invikafusp Alfa Data in PD-1-Resistant Solid Tumors and Appoints Pembrolizumab Development Leader Eric Rubin, M.D., to Scientific Advisory Board

Published

on

Updated STARt-001 results will highlight invikafusp alfa’s single-agent activity in PD-1–resistant tumors using a biomarker-enrichment strategyEric Rubin, former Senior Vice President of Global Clinical Oncology at Merck, who led the initial development of pembrolizumab (KEYTRUDA®) through its global regulatory approvals, joins Marengo to guide invikafusp alfa’s next phase

CAMBRIDGE, Mass., July 20, 2026 /PRNewswire/ — Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision immunotherapies, today announced that key Phase 2 data from the ongoing STARt-001 study of invikafusp alfa, a first-in-class bispecific dual T-cell agonist, have been selected for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026. The presentation will evaluate invikafusp alfa’s single-agent activity in patients whose cancers have progressed following PD-1–directed treatment, using biomarker-enriched cohorts to identify patients most likely to benefit. The company also appointed renowned oncology drug developer Eric Rubin, M.D., to its Scientific Advisory Board.

The ESMO presentation will feature updated clinical and translational data from tumor mutational burden-high (TMB-H) patients with advanced solid tumors that are refractory or resistant to PD-1–directed therapy. Building on data reported at SITC 2025, the results will further assess whether selective activation of Vβ6/Vβ10 T-cell subsets in vivo can generate single-agent activity across biomarker-enriched tumor types after PD-1 resistance.

“Selection of our Phase 2 data for an ESMO oral presentation reflects the encouraging clinical efficacy signal from the ongoing Phase 2 study of invikafusp alfa and its differentiated biology,” said Zhen Su, M.D., M.B.A., Chief Executive Officer of Marengo Therapeutics. “STARt-001 is designed to test single-agent activity after PD-1–directed treatment has stopped working, using a biomarker-enriched strategy such as TMB-H. These studies will help us determine whether selective activation of Vβ6/Vβ10 T-cell subsets can support a broader pan-tumor development strategy. Eric led the initial development of KEYTRUDA® and its broad immuno-oncology backbone development strategy, and his experience will be invaluable as we rigorously evaluate invikafusp alfa’s potential.”

Dr. Rubin’s appointment strengthens Marengo’s scientific leadership in precision T-cell activation research as invikafusp alfa enters its next stage of development. His experience leading the initial development of KEYTRUDA® and large-scale oncology clinical programs will inform Marengo’s strategy for evaluating invikafusp alfa for single-agent activity in biomarker-selected, heavily pretreated PD-1–resistant cancers and, over time, as a potential combination backbone in larger and earlier-line settings.

“Invikafusp alfa is one of the more compelling novel immunotherapy approaches I have seen in recent years,” said Eric Rubin, M.D. “Its precision T-cell agonist mechanism provides a strong rationale for testing single-agent activity after PD-1 resistance while avoiding broad activation of the entire T-cell compartment. The biomarker-enriched design of STARt-001 should help define the patients and tumor settings in which this approach may offer the greatest benefit and inform its potential role in future combination strategies.”

Dr. Rubin brings more than 35 years of cancer drug-development experience across academic and industry settings, including leading large-scale oncology clinical programs. Most recently, he was Senior Vice President of Global Clinical Oncology at Merck, where he held several senior leadership roles during his 16-year tenure and led the initial development of pembrolizumab (KEYTRUDA®). Earlier, he served on the faculty of Dana-Farber Cancer Institute and as Director of Investigational Therapeutics at Rutgers Cancer Institute of New Jersey, with a research focus on oncology translational science.

Dr. Rubin has authored more than 100 peer-reviewed publications and served on national research and policy committees, including for the National Cancer Institute, American Cancer Society, American Association for Cancer Research and American Society of Clinical Oncology.

Presentation Details:

Title: START-001: Phase 2 results of invikafusp alfa, a first-in-class T cell receptor β-chain–targeted bispecific antibody, as monotherapy in patients with TMB-H solid tumors resistant to immune checkpoint blockade (ICB)Conference: ESMO Annual Meeting 2026Session Category and Title: Proffered paper: Investigational immunotherapySession Date and Time: Friday October 23 2026, 1:30 – 3:00 PM CETPresentation Number: #4703Presenter: Dr. Elena Garralda

About Marengo Therapeutics
Marengo Therapeutics, Inc. is a clinical-stage biotechnology company developing TCR-targeting antibodies that selectively modulate disease-relevant T-cell subsets for cancer and autoimmune diseases. Its three proprietary platforms—Selective T Cell Activation Repertoire (STAR), Trispecific T Cell Engager (TriSTAR) and T Cell Depletor (MSTAR)—are designed to target the right T cells in the right patients. To learn more, visit marengotx.com.

About Invikafusp alfa (STAR0602)
Invikafusp alfa (STAR0602), the lead candidate from Marengo’s STAR™ platform, is designed to selectively activate Vβ6/Vβ10 T-cell subsets found across cancers by combining non-clonal TCR activation with an IL-2 signal in a single molecule. This precision approach is intended to generate durable antitumor immunity while limiting broader systemic immune activation. Marengo is evaluating invikafusp alfa’s single-agent activity in biomarker-selected, PD-1–resistant cancers and its longer-term potential as a combination backbone.

About the STARt-001 Clinical Study 
STARt-001 is a global Phase 1/2 trial evaluating invikafusp alfa monotherapy in patients with advanced, antigen-rich solid tumors that are refractory or resistant to PD-1–directed therapy. The Phase 2 portion uses biomarker-enriched cohorts, including TMB-H and MSI-H, to assess activity across multiple tumor types and help identify patients most likely to benefit. For more information, visit ClinicalTrials.gov (NCT05592626).

Marengo Contacts:
Media | Peg Rusconi | peg.rusconi@deerfieldgroup.com
Investors | bd@marengotx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/marengo-secures-esmo-2026-oral-presentation-for-key-phase-2-invikafusp-alfa-data-in-pd-1resistant-solid-tumors-and-appoints-pembrolizumab-development-leader-eric-rubin-md-to-scientific-advisory-board-302829182.html

SOURCE Marengo Therapeutics

Continue Reading

Technology

JustMarkets Explores What CFD Traders May Consider When Trading Volatility-Based Instruments

Published

on

By

HO CHI MINH CITY, Vietnam, Sept. 28, 2026 /PRNewswire/ — JustMarkets, a multi-asset CFD broker, has released an analysis of volatility-based instruments and the practical factors CFD traders may consider before trading them. According to the analysis, without volatility there may be little room for short-term trading — one of the reasons volatility-based instruments may attract attention from CFD traders seeking markets with distinct price behavior.

Unlike conventional assets, which can experience price fluctuations triggered by economic data releases, companies’ financial performance, central bank actions, or geopolitical events, volatility-based instruments may be constructed around specific market behavior.

What May Draw the Attention of Active CFD Traders

JustMarkets notes that exposure to price movement is the first factor.

Conventional markets experience calm and volatility based on liquidity, trading sessions, releases, and news. Meanwhile, volatility-based instruments exhibit specific characteristics, relevant for active CFD traders using technical strategies like momentum, breakout, and intraday-range approaches. Another factor is trading availability. Depending on the instrument, volatility-based instruments trade outside conventional exchange hours, giving CFD traders flexibility in timing analysis and trading. However, price movement alone does not mean improved conditions.

Increased Volatility Brings Higher Risk

Volatility can work in both directions. An instrument that can move quickly in a trader’s favor can also move quickly against the position. When trading leveraged CFDs, risk management becomes one of the most important factors.

Leverage allows CFD traders to control larger market exposure with limited margin. However, leverage also increases market exposure, capital volatility, and the potential for losses, and can lead to greater losses during adverse price movements.

Before placing a trade on any CFD instrument, traders should understand its price behavior, spreads, commissions, margin requirements, trading hours, overnight costs, and other factors.

JustMarkets notes that the key question before making a trading decision is not “Is this instrument volatile?” but rather “Does this kind of volatility fit my trading and risk management strategy?”

What to Check Before Trading

Before choosing a volatility-based CFD, traders may consider several practical factors:

Price behavior: how quickly and how often the instrument moves.Trading costs: spreads, commissions, and potential overnight charges.Leverage and margin: how much market exposure the position creates.Trading hours: when the instrument is available for trading.Risk tolerance: whether the instrument’s volatility aligns with the trader’s strategy and acceptable level of risk.

Shifting Focus to Market Behavior

For active CFD traders, an instrument’s price behavior may be just as important as the asset class it belongs to.

Depending on their strategy, scalpers may focus more on short-term price movements, spreads, and execution, while day traders may pay closer attention to intraday volatility and trading costs. Swing traders, meanwhile, may also consider how price behavior develops over a longer holding period, as well as potential overnight costs.

The same principle applies to the CFD markets offered by JustMarkets. CFD traders can choose among CFDs on different types of global markets and assess instruments based on their trading approach.

Volatility-based instruments may offer CFD traders more trading opportunities, but they also carry higher risk. Volatility should never be seen as a shortcut to profits.

For CFD traders, understanding an instrument’s price behavior and how it aligns with their trading strategy comes first.

JustMarkets aims to provide a convenient and transparent trading environment for CFD traders.

Risk Warning: 

Trading Forex and CFDs involves significant risk and can result in the loss of your invested capital. This article is for informational purposes only and does not constitute investment advice. 

 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/justmarkets-explores-what-cfd-traders-may-consider-when-trading-volatility-based-instruments-302892169.html

SOURCE JustMarkets

Continue Reading

Technology

TECO Showcases Integrated Modular Data Center Solutions in Singapore, Targeting Southeast Asia’s AI Infrastructure Opportunities

Published

on

By

SINGAPORE, Sept. 29, 2026 /PRNewswire/ — TECO Electric & Machinery Co., Ltd. (TWSE: 1504), together with its subsidiary TECOBAR, made its debut at Data Center World Singapore today (29th), showcasing its integrated one-stop capabilities in data center power systems and Modular Data Centers (MDCs) as it expands into Southeast Asia’s AI infrastructure market. TECO President Fei-Yuan Kao stated, “As global competition for AI computing power intensifies, deployment speed and power supply stability have become critical to competitiveness. With more than 20 years of experience in data center infrastructure and cumulative contracted project capacity totaling nearly 1 GW, TECO integrates electromechanical systems, power systems, engineering, and modular prefabrication capabilities to help global customers accelerate AI data center deployment, bring computing capacity online sooner, and shorten time to commercial operation.”

Five Core MDC Modules Accelerate AI Data Center Deployment
The exhibition focuses on TECO’s one-stop Modular Data Center delivery capabilities, featuring five core modules: IT systems, cooling systems, power systems, generator systems, and energy management and control systems (EMS). It also demonstrates TECO’s full-service capabilities spanning requirements analysis, system design, engineering planning, equipment manufacturing, modular prefabrication, system integration, on-site installation, testing, and handover. TECO is also presenting an ongoing 10 MW Modular Data Center project to illustrate the five core modules, from integrated design and factory prefabrication to on-site installation. Flexibly configured based on customer requirements, site conditions, and reliability tiers, TECO’s MDC solutions reduce construction complexity and project timelines while improving engineering quality and energy efficiency.

Integrating Power Equipment and Local Manufacturing to Strengthen Supply Chain Services
High-performance computing applications continue to increase data center power density, making the safety, reliability, and deployment efficiency of power transmission systems increasingly critical. TECO has integrated the Group’s equipment manufacturing and system integration resources, with its subsidiary TECOBAR showcasing armored and cast-resin busway products. Their high current-carrying capacity, modular design, and rapid deployment capabilities address different AI data center requirements. TECOBAR’s new armored busway plant in Penang, Malaysia, is designed for annual production capacity of 400,000 meters. Its products are certified to international standards including IEC and UL, strengthening TECO’s supply chain service capabilities for data center customers across Southeast Asia and global markets.

About TECO
Founded in 1956, TECO has evolved into a major global business group, with the objective of becoming the key driver in realizing global electrification, intelligence, and green energy. https://www.teco.com.tw/en-us/

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/teco-showcases-integrated-modular-data-center-solutions-in-singapore-targeting-southeast-asias-ai-infrastructure-opportunities-302892175.html

SOURCE TECO Electric & Machinery Co., Ltd.

Continue Reading

Technology

Cambridge English Educational Partners support Malaysian young learners in the age of AI

Published

on

By

SINGAPORE, Sept. 29, 2026 /PRNewswire/ — As technologies such as Artificial Intelligence (AI) become increasingly important for the next generation, kindergartens and language schools in Malaysia are preparing young learners with strong English communication skills for the future.

Cambridge English Educational Partners support institutions in this journey through a holistic approach to English teaching, learning and assessment. Partner institutions use Cambridge English learning materials, teacher training and teaching qualifications, and globally recognised tests and exams to strengthen teaching standards and help learners develop and prove their English skills.

Jacelyn Tan, Academic Principal at KLC Language Centre, a Cambridge English Educational Partner in Malaysia, explains how the centre prepares young learners for an AI-driven future.

“Unlike traditional language centres in Malaysia, KLC maintains an intentional, high-attention learning environment with ultra-small class sizes. This focused approach of highly personalised teacher guidance and a unique, structured curriculum ensures that young learners rapidly build real-life communication confidence alongside global qualification excellence with Cambridge English.”

Tan Shi Yunn, Deputy Head of Kindergartens at Young’s Kingdom, explains how its network of kindergartens uses Cambridge English resources to support children aged 3 to 6 in their English language journey.

“Our curriculum is structured around thematic learning and hands-on activities that nurture creativity, problem-solving and curiosity. Through guided exploration, children find joy in learning and develop a genuine love for school.

“We focus on holistic development of young learners that balances academic, emotional, social and physical growth.

“Young’s Kingdom’s integration of Cambridge English resources into our curriculum has significantly strengthened the quality of English language teaching and learning. The well-structured materials, assessments and professional development opportunities for our teachers have helped our students build greater confidence, communication skills and academic readiness in English.”

Strong English communication skills will be critical in helping young learners become future-ready. Cambridge English Educational Partners support institutions such as KLC Language Centre and Young’s Kingdom with learning materials, teacher development and globally recognised qualifications to strengthen their English teaching and learning journeys.

KLC Language Centre, Malaysia

Small Class Sizes: KLC’s small classes enable highly personalised guidance through a structured curriculum, helping learners progress through CEFR levels and reach Cambridge assessment milestones in as little as four months.

Real-Life Communication Confidence: Personalised teaching and a structured learning approach help young learners build practical communication confidence alongside internationally recognised qualifications.

“As the first Cambridge English Educational Partner in Malaysia, our long-standing collaboration with Cambridge has helped elevate literacy standards across our branches. By integrating Cambridge English learning frameworks across digital and classroom learning, we have guided tens of thousands of young learners towards recognised qualifications. Cambridge assessments also provide parents with clear, measurable benchmarks of their child’s global English proficiency.”

Jacelyn Tan
Academic Principal

Young’s Kingdom, Malaysia

Young’s Kingdom is a network of private preschools and kindergartens across Johor Bahru, Malaysia, providing holistic education for children aged 3 to 6.

Play-Based Learning
Thematic, hands-on activities develop creativity, problem-solving, curiosity and a love for learning.

Tri-Language Proficiency
Children learn English, Bahasa Melayu and Mandarin, with English as the main communication medium.

Strong Academic Foundation
Core programmes include languages, Mathematics, Science, Jolly Phonics and Cambridge English for 6-year-olds, preparing children for primary school.

“The integration of Cambridge English resources has strengthened our English teaching and learning. Its structured materials, assessments and teacher development help students build confidence, communication skills and academic readiness, while equipping our teachers with internationally aligned teaching practices.”

Teacher Tan Shi Yunn
Deputy Head of Kindergarten

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/cambridge-english-educational-partners-support-malaysian-young-learners-in-the-age-of-ai-302892211.html

SOURCE Cambridge English

Continue Reading

Trending